Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Chlorproguanil/dapsone/artesunate
Другие языки:

    Chlorproguanil/dapsone/artesunate

    Подписчиков: 0, рейтинг: 0
    Chlorproguanil/dapsone/artesunate
    Combination of
    Chlorproguanil Antimalarial drug
    Dapsone Antibiotic
    Artesunate Antimalarial drug
    Legal status
    Legal status
    • Development halted
    Identifiers
    ChemSpider
    • none

    Chlorproguanil/dapsone/artesunate (abbreviated CDA) was an experimental antimalarial treatment that entered Phase III clinical trials in 2006. Development was halted because it was associated with an increased risk of haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency.

    It consists of chlorproguanil, dapsone, and artesunate. (It can also be interpreted as Lapdap+artesunate.)

    Studies compared this combination against artemether/lumefantrine (Coartem) and against chlorproguanil/dapsone (Lapdap). This drug was developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.

    External links


    Новое сообщение